Introduction: Kayakarpam therapies are known for rejuvenation, delaying ageing and improving vitality. Boerhavia diffusa (Mookirattai) is a well-known Siddha drug indicated mainly for Vatha disorders, which are often associated with neurological dysfunctions. However, experimental evidence for its neuroprotective effect is limited. Therefore, the present study evaluates its activity using an in-vitro model. Aim: To evaluate the neuroprotective potential of Mookirattai Ilai Karpam through in-vitro acetylcholinesterase inhibition. Methods: The formulation was prepared following classical Siddha procedures. Neuroprotective activity was assessed by an in-vitro AChE inhibition assay at different concentrations, and the percentage inhibition was compared with a standard drug. Results: Mookirattai Ilai Karpam showed dose-dependent inhibition of AChE. Higher concentrations exhibited notable activity, suggesting possible enhancement of cholinergic transmission. Conclusion: The study demonstrates that Mookirattai Ilai Karpam has significant acetylcholinesterase inhibitory activity, supporting its traditional use in Vatha-related neurological conditions. Further in-vivo and clinical validation is needed.
Dr. P. Lavanya1*, Dr. S. S. Selvapriya, 2Dr. S. M. Chitra3 (Wed,) studied this question.